Effectiveness of Intranasal Dexmedetomidine Premedication in Child Intubation

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

December 28, 2024

Study Completion Date

January 10, 2025

Conditions
Elective Surgical ProcedureASA Physical Status IASA Physical Status II
Interventions
DRUG

Intranasal dexmedetomidine

Intranasal dexmedetomidine at a dose of 2 mcg/kg body weight, diluted in 1 mL of 0.9% NaCl, administered using a 1 mL syringe connected to a Teleflex MAD Nasal device while in the supine position. The soft tip of the device will be gently placed into each nostril without applying pressure. The solution will be sprayed slowly to create a fine mist. The total dose will be divided equally, with 0.5 mL delivered into each nostril, administered approximately 30 minutes before intubation during induction.

DRUG

0.9% NaCl solution

Participants will receive 1 ml of 0.9% NaCl solution administered intranasally using a 1 ml syringe connected to a Teleflex MAD nasal device while in the supine position. The soft tip of the Teleflex MAD nasal device is gently placed into each nostril without applying pressure. The solution is slowly sprayed to create a fine mist for patient comfort. The dose is divided equally, delivering 0.5 ml into each nostril, approximately 30 minutes before intubation during induction.

Trial Locations (1)

10430

Cipto Mangunkusumo Hospital, Jakarta

All Listed Sponsors
lead

Indonesia University

OTHER

NCT06991647 - Effectiveness of Intranasal Dexmedetomidine Premedication in Child Intubation | Biotech Hunter | Biotech Hunter